FilingSEC EDGAR8-K
Orchestra BioMed Exceeds Enrollment Target in BACKBEAT Global Pivotal Trial
· SEC accepted
Filing content
The company announced that it has surpassed its enrollment target of 316 patients, with 330 patients randomized in the BACKBEAT trial as of September 30, 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…